Publication Name	World Journal of Pharmacology
Manuscript ID	15571
Country	United States

Received	2014-11-29 13:38
Peer-Review Started	2014-11-29 15:46
To Make the First Decision	2015-01-08 14:00
Return for Revision	2015-01-14 14:16
Revised	2015-01-28 00:45
Second Decision	2015-03-16 17:49
Accepted by Journal Editor-in-Chief	2015-03-16 21:08
Accepted by Executive Editor-in-Chief	2015-04-02 16:21
Articles in Press	2015-04-02 16:21
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-06-01 16:00
Publish the Manuscript Online	2015-06-19 15:32

ISSN	2220-3192 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Tropical Medicine
Manuscript Type	Minireviews
Article Title	Therapeutic options and vaccine development in the treatment of leishmaniasis
Manuscript Source	Invited Manuscript
All Author List	Jill E Weatherhead and Laila Woc-Colburn
Funding Agency and Grant Number
Corresponding Author	Laila Woc-Colburn, MD, DTM&H, FACP, Department of Medicine, Baylor College of Medicine, Room BCM164A, One Baylor Plaza, BCM113, Houston, TX 77030, United States. woccolbu@bcm.edu
Key Words	Leishmania; Visceral; Cutaneous; Mucocu­taneous; Amphoterecin; Vaccine
Core Tip	Leishmaniasis is an old disease, hard to diagnose and even harder to treat. Limited treatment is available. Early treatment of leishmaniasis is critical to achieve cure, prevent psychological and social distress, and prevent transmission of disease. Untreated Leishmaniasis - cutaneous leishmaniasis, mucocutaneous leishmaniasis and visceral leishmaniasis - results in disfiguring scars and high rates of morbidity and mortality in highly endemic regions of the world. Cure rates with available therapeutics are limited due to cost, therapeutic toxicity and the growing rate of resistance. There is an emergent need for development of new therapeutic options with improved tolerability, improved healing process minimizing scarring, and improved efficacy amongst all Leishmania spp.
Publish Date	2015-06-19 15:32
Citation	Weatherhead JE, Woc-Colburn L. Therapeutic options and vaccine development in the treatment of leishmaniasis. World J Pharmacol 2015; 4(2): 210-218
URL	http://www.wjgnet.com/2220-3192/full/v4/i2/210.htm
DOI	http://dx.doi.org/10.5497/wjp.v4.i2.210

Full Article (PDF)	WJP-4-210.pdf
Full Article (Word)	WJP-4-210.doc
Manuscript File	15571-Review.docx
Answering Reviewers	15571-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	15571-Conflict-of-interest statement.pdf
Copyright License Agreement	15571-Copyright assignment.pdf
Peer-review Report	15571-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	15571-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	15571-Scientific misconduct check.pdf
Scientific Editor Work List	15571-Scientific editor work list.pdf